is cbd oil used for cancer treatment

Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo controlled, randomised clinical trial of efficacy and safety of cannabidiol (CBD)

Despite improvements in medical care, patients with advanced cancer still experience substantial symptom distress. There is increasing interest in the use of medicinal cannabinoids, but there is little high quality evidence to guide clinicians. This study aims to define the role of cannabidiol (CBD) in the management of symptom burden in patients with advanced cancer undergoing standard palliative care.

Methods and design

This study is a multicentre, randomised, placebo controlled, two arm, parallel trial of escalating doses of oral CBD. It will compare efficacy and safety outcomes of a titrated dose of CBD (100 mg/mL formulation, dose range 50 mg to 600 mg per day) against placebo. There is a 2-week patient determined titration phase, using escalating doses of CBD or placebo to reach a dose that achieves symptom relief with tolerable side effects. This is then followed by a further 2-week assessment period on the stable dose determined in collaboration with clinicians.

Discussion

A major strength of this study is that it will target symptom burden as a whole, rather than just individual symptoms, in an attempt to describe the general improvement in wellbeing previously reported by some patients in open label, non controlled trials of medicinal cannabis. Randomisation with placebo is essential because of the well-documented over reporting of benefit in uncontrolled trials and high placebo response rates in cancer pain trials. This will be the first placebo controlled clinical trial to evaluate rigorously the efficacy, safety and acceptability of CBD for symptom relief in advanced cancer patients. This study will provide the medical community with evidence to present to patients wishing to access medicinal cannabis for their cancer related symptoms.

Trial registration number

ALCTRN12618001220257 Registered 20/07/2018.

Background

Despite advances in medicine, patients with advanced cancer can still experience substantial symptom burden that causes distress [1]. Palliative care aims to provide a patient-centred, holistic approach to improve patients’ health and well-being. There is a wide range of medications available, but the control of many symptoms (e.g. pain, nausea, anorexia, anxiety,) remains an ongoing challenge [2].

There is increasing interest in the use of medicinal cannabinoids for the relief of symptoms in palliative care patients [3]. There has been changes in legislation in Australia (both federally and in states) that has now provided pathways to prescribe medicinal cannabinoids for a range of indications for a number of indications including – palliative care, intractable epilepsy, chronic pain, spasticity associated with multiple sclerosis, and chemotherapy induced nausea and vomiting (CINV) [4].

Cannabis contains more than 500 bioactive compounds, including more than seventy different cannabinoids [5]. The main cannabinoids are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is thought to be the main psychoactive component of cannabinoids Potential benefits of THC can include pain control,, nausea improvement, and relaxation of muscles with potential side effects including psychosis, sedation and intoxication. The recommended dose range for oral THC varies from 2.5 to 40 mg/day [6]. CBD is not intoxicating, and in animals has demonstrated some benefits in anxiety, psychosis, inflammation, epilepsy and demonstrated neuroprotective effects [7]. CBD is also considered to mediate many of the adverse psychotropic effects of THC, although this research is still emerging [8]. CBD has been used with a dosing in the range of 40 to 1280 mg/day orally [9].

There is little high quality evidence of benefit to date for the use of medicinal cannabinoids. The most recent review from the USA National Academies of Sciences, Engineering, and Medicine found evidence for the use of medicinal cannabinoids for treatment of some types of chronic pain, CINV and spasticity in multiple sclerosis in some patients, with moderate evidence for sleep disorders [10]. Cannabinoid products are licensed for a range of conditions in different countries, with little consistency between countries for indication and dosing [11]. Whilst cannabinoids may have potential clinical benefits, their use is not without possible adverse effects and further research is needed define their role in medical practice [3, 11].

There are many unknowns when it comes to prescribing medicinal cannabis [11]. This includes the formulation of the product, the ratios of THC or CBD, dosing levels and the best route of delivery. Ongoing concerns remain around the uncertainty over toxicity and abuse potential. The 1:1 THC/CBD ratio used in formulations may deliver sufficient CBD to ameliorate the psychotoxic effects of THC, but is unlikely to produce significant CBD therapeutic effects.

We hypothesize that a higher CBD dose is required in order to deliver therapeutic effects. However, to date there has been no formal examination of the effect of different dose of CBD. We will therefore compare efficacy and safety outcomes of a dose escalated 100 mg/mL formulation against placebo, with CBD escalated to doses previously shown to be safe.

Methods

Aims and objectives

This study aims to define the role of CBD in the management of symptoms in patients with advanced cancer undergoing standard palliative care. The hypothesis is that medicinal cannabinoids will reduce the total symptom burden in these patients compared to placebo.

The primary objective is to assess the effect of escalating doses of a CBD against placebo on total symptom scores at day 14, as measured by the Edmonton Symptom Assessment Scale (ESAS) [12]. Secondary objectives are to establish a patient determined effective dose range of the CBD, to assess the effect on symptom scores at days 7, 21 and 28, the change in total physical and emotional sores, global impression of change, anxiety and depression, opioid use, quality of life, and to document adverse effects associated with CBD use at different dosages.

Study design

This study is a multicentre, randomised, placebo controlled, two arm parallel trial of escalating doses of oral CBD (100 mg/ml oil formulation). There is a 2-week patient determined titration phase, using escalating doses of CBD or placebo, to reach a dose that achieves symptom relief with tolerable side effects. This is then followed by a further 2-week assessment period on the stable dose determined in collaboration with clinicians.

Eligible patients will be randomly assigned in equal numbers to one of the two study arms. Randomisation schedules will be developed for each site using random number tables, computer generated at an independent centre. Treatment for each patient will be allocated according to a block randomisation schedule held by the central registry. Block randomisation within each centre will ensure uniform allocation to each arm in each site. Pharmacy will be notified of a participant, and a completed script with the participant’s study ID number will be given to the site pharmacy. The pharmacist will randomise the participant according to the schedule and dispense the medication in a labelled bottle. The participant ID, allocation number, date of request, preparation and dispensing will be recorded in a log maintained by the site pharmacist for each randomisation.

All participants, caregivers, investigators and clinical staff will remain blind to study assignment until trial completion. The code will only be broken in cases of a clinical emergency. An investigator not directly involved in the randomisation of patients will keep a blinded copy of the randomisation schedule and will be contacted in the event of the need to un-blind. All study drugs and placebo will be in oil solution form and identical in appearance. All oil solutions will be matched for taste, colour and bottle size to preserve the blinding irrespective of the contents, each participant will receive the oil solution in a prepacked bottle labelled with their individual trial participation ID number, and consecutively numbered according to the randomisation scale.

Intervention

Arm 1 of the trial consists of CBD 100 mg oral oil solution (GD Pharma Pty Ltd) and Arm 2 a matching placebo oral oil solution. Participants are asked to take daily doses as per dosing schedule instructions. The study drug is to commence on the day of baseline assessment, continuing for a maximum of 28 days.

The cannabinoid oils and placebo will be dispensed in identical 25 mL bottles containing a sufficient quantity of oil. Participants will be given replacement bottles to complete the study as required. Participants will be educated on how to administer daily doses using supplied 1 mL syringes appropriate for the dose. Cannabinoid oil that has been allocated to a participant and not used will be returned to the research nurse/research officer and destroyed by local pharmacy as per pharmacy guidelines.

Dose titration will be confirmed following regular consultation. Each participant will be advised to increase their dose according to a schedule until they are satisfied with their symptom improvement or they experience unacceptable side effects. Dose titration downwards will also be allowed, in consultation with research staff. The participant in collaboration with research staff will define the dose level at which they will continue until the primary outcome point of 14 days. Participants will then be given the option of remaining on the blinded oil solution for a further 2 weeks (28 day total) for continuing assessment of efficacy and adverse events. Assessment at 28 days is a secondary end-point.

Participants will be recruited from five sites of the Queensland Palliative Care Research Group (QPCRG). It is anticipated that this will be predominately an outpatient study.

All participants will be given standard palliative care according to the local practice of the recruiting centre [12]. They will continue all current medications including opioids, antiemetics, sedatives and specific anti-cancer therapy (including chemotherapy, immunotherapy, and radiotherapy).

Study participants

Patients who meet the inclusion criteria will have an advanced histologically proven cancer diagnosis (metastatic or locally advanced), be known to and be receiving palliative care at the recruiting centre, have an ESAS Total Symptom Distress Score (TSDS) of ≥10/90 for cancer-related symptoms, and at least one individual ESAS score ≥ 3/10 [13]. They must have a Performance Status AKPS (Australia-modified Karnofsky Scale score) of ≥30/100 [14], be aged ≥25 years, have a negative THC urine test at commencement of trial, be able to tolerate oral medications and must be either English-speaking or have an interpreter available.

Participants must have a negative pregnancy urine test at eligibility (only if of reproductive potential) and agree to avoid pregnancy during the study and 12 weeks following the last dose of the study drug. Males must agree to avoid fathering a child and to not donate sperm during the study and for at least 12 weeks following the last dose of the study drug. Further to this the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) [15] will be conducted to determine eligibility. It is designed to determine whether harmful substance are being used and go undetected or become worse. The assessment is comprised of 8 questions assessing, tobacco, alcohol, cocaine, amphetamine-type stimulants, sedatives, hallucinogens, opiates and ‘other drugs’.

Exclusion criteria will include a history of hypersensitivity to any cannabinoid, unstable untreated cardiovascular disease, severe hepatic impairment (total bilirubin ≥1.5 times the upper limit of the normal range, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) ≥3.0 times the upper limit of the normal range; subjects with liver metastasis may have an AST and ALT of ≥5.0 times the upper limit of normal), severe renal impairment (eGFR ≤20 mL/min/1.73 m2), a history of psychiatric disorders (severe depression or anxiety, personality disorder, psychosis, schizophrenia, first degree relative with schizophrenia and/or suicidal ideation), cognitive impairment (SLUMS – St Louis University Mental Status examination ≤20/30) [16] and a known substance use disorder (ASSIST – Alcohol, Smoking and Substance Involvement Screening Test) examination scoring > 27 for any substance).

Potential participants will be excluded if they have a history suggesting that drug diversion may be a risk for them or their family/carers, have participated in a trial of a new clinical entity within the last 28 days, or treatment with a new specific anticancer agent (chemotherapy, targeted or hormonal therapy) or radiation within the previous 7 days.

Consent process

The process for obtaining consent for this study will be exchanging information between the study staff and potential participants and any other person the participant wishes to include in the discussion. A participant information sheet (PICF) will be provided in written form and will be used as the basis for the discussion. This will cover the purpose, expected procedures, participant requirements, risks, benefits, burdens and side effects that are expected or possible during the study. Potential participants will be given the opportunity (in time and physical capacity) to consider the study, formulate any questions. All questions will be addressed and answered fully. An actual time point for consent will not be specified as this will be determined by the person’s physical condition. The consent form is to be completed by trained study team members in accordance with the requirements of the approving ethics committee. The form is to be signed and dated by the participant.

Assessments

Participants will receive 2 times/weekly research nurse phone calls in the first 2 weeks and out-patient clinic medical review visits at days 7, 14, 21 day 28, with outcome measures at these points.

Symptom burden will be measured using the Edmonton Symptom Assessment Scale (ESAS). Confirmed documented disease status will be assessed at days 14 and 28, where applicable.

A routine haematology and biochemistry screen including liver function tests will be taken at eligibility/baseline assessment. Blood for C-reactive protein (CRP) as a basic test of inflammation will be taken at baseline, day 14 and day 28. All consenting participants will have a urine test to exclude recent use of THC related products as a pre screen.. At day 14 a urine sample will be collected and stored (frozen) until the completion and un-blinding of the study. Samples will be stored on site and transported to central storage in batches over the course of the study. These samples will be for post-trial analysis for evidence of no THC product use during the trial.

Participants will be contacted at day 56 (+ 4 weeks post last dose). Date of death will be recorded for all participants up the census point. The study schedule can be viewed in Table 1.

Outcomes and assessment tools

The primary outcome is a change from baseline of total ESAS TSDS at day 14. Clinically significant change is determined to be an improvement of the TSDS of ≥6.

The ESAS is a 9 item inventory rated on a 11 point scale anchored at 1 (no problem) to 10 (worst problem). It assesses both physical and psychological symptoms, plus general wellbeing. It has been validated in the assessment of symptoms in cancer patients [13].

Secondary Outcomes include:

Patient determined effective dose of CBD formulation, defined as the dose that achieves symptom relief with acceptable side-effects.

ESAS TSDS at days 7, 21 and 28.

Physical and emotional ESAS scores at each time point.

Physical scores will be measured by The Australia modified Karnofsky Performance Status (AKPS) and Resource Utilisation Groups- Activities of Daily Living Scale (RUG-ADL). The AKPS is a validated variant of the Karnofsky Performance Status. The Australian version can be applied to both in and outpatients and is sensitive to changes in function over time [14]. The RUG-ADL is an instrument developed for the measurement of nursing dependency. The ADL scale measures patients’ needs for assistance in activities of daily living (eating, bed mobility, transferring and toileting) [17].

Individual symptom scores (descriptive analysis only).

Oral morphine equivalent (OME), average use at baseline and weekly.

SLUMS score baseline and day 14.

A person’s capacity to understand the study will be measured using the St Louis University Mental Status Examination. This tool is more sensitive than the Mini Mental Status Examination, and takes school education into account in the score. A score of 23 out of 30 will be considered an appropriate score to assess the ability to complete the study assessments [16].

Patient Global Impression of Change (PGIC), days 7 and 14, 21 and 28

This is a subjective measure of symptom change done by the patient themselves [18].

Clinical Global Impressions (CGI) Scale, days 7 and 14, 21 and 28

This is a subjective measure of symptom change done by the investigating clinician [18].

DASS-21 score baseline, days 14 and 28

DASS-21 is a self-reported 21-item scale, 7 questions per sub-item questionnaire measuring depression, anxiety and stress. The DASS-21 will be used for assessment at baseline (day 0), days 7, 14 and 28 19 EORTC score QoL baseline, days 14 and 28 [19, 20].

This is a QoL measure found valid for use in a wide variety of cancer populations. To reduce patient burden, we will use the 15 question subset commonly used for the palliative care population.

NCI common terminology for adverse events V4.03, day 2, 4, 7, 9, 11, 14, 16, 18, 21, 23, 25 and 28 [21].

The NCI CTCAE is a severity grading system for adverse events. Adverse events relate to an unfavourable or unintended sign, symptom or disease temporarily associated with a medical treatment or a procedure which may not be related to the medical treatment or procedure. The CTCAE has a grading of 1 (Mild) to 5 (Death). The known common adverse events associated with cannabinoids are: confusion, somnolence, paranoia, anxiety, mood changes, psychosis, hypertension, tachycardia, hyperhidrosis, nausea, vomiting and abdominal pain [21].

The study will assess adverse events (AE) and serious adverse events (SAE) using the criteria of the NCI, CTCAE V4 [21]. The known common AEs associated with CBD will be specifically addressed at each time point, including dry mouth, diarrhoea, light headedness and drowsiness, nausea, vomiting and abdominal pain). Finally, a detailed concurrent medication list is to be updated and recorded at baseline (day 0), days 7, 14, 21 and 28. This is to include over the counter medications, prescribed medications, complementary and antiemetic medication.

Statistical analysis and sample size

Allowing 20% for attrition, and with improvement of ≥6 for CBD compared to placebo, it is anticipated that 144 participants (72 per arm) should be randomized to achieve a sample size of 60 participants per arm, assuming 80% power, a simple random sampling scheme and a Type 1 error of 5% (two-tailed), and a standard deviation of 11.6. The sample size is based on previous work by Hui et al. [13], who determined the minimal clinically important difference in the TSDS to be 5.7 [13]. As such we have elected to use an improvement of ≥6 in the TSDS as the primary outcome measure. The superiority of the CBD arm compared to placebo will be tested by comparing the response to each arm after 14 days, relative to baseline. Descriptive analyses and frequency distributions will be generated from participants’ demographic and clinical characteristics, with all variables explored using graphical methods and summary statistics. In univariate analysis, t-tests or the corresponding non-parametric tests (Wilcoxon Rank Sum) will be used to test for differences in change in total symptom distress scores of CBD versus placebo. Generalised estimating equation models with the appropriate link function will be developed to assess the effect of treatment and confounders and/or modifying factors on the primary and secondary outcomes and account for within subject correlation where required. This study is powered to detect superiority of CBD over placebo.

An interim analysis will be performed after 50% participants have completed 14 days of the trial. The analysis will be performed by a biostatistician blinded for the treatment allocation and reported to the investigators and the Data Safety Monitoring Board (DSMB). The purpose of the interim analysis is primarily to monitor and ensure safety of participants rather than evidence of such benefit that early stopping of the trial is justified. AEs and SAEs will be stratified by type and severity. The frequency of AEs and SAEs will be compared between treatment groups using chi-square test and logistic regression if indicated to adjust for any baseline differences between groups. If this shows a significant difference the investigators and DSMB will be un-blinded to the study groups and make any stopping decision on the basis of the nature of any AEs and/or SAEs and ethical grounds, as well as consideration of any statistical differences between the groups. Grounds for stopping on evidence of clear benefit will be considered.

Data collection and management

Data will be sourced from a number of modes. The study is mainly based in the outpatient clinic, so most data will be collected from the participant and recoded in the corresponding CRF or questionnaires. Some data will be collected from medical records, but the majority of the data will be collected from:

Measure Source Collected by
General medical information Clinical record Medical officer
General demographic data Clinical record Study nurse
Pathology results – blood Pathology report Pathology
Pathology results – urine Clinical record Study nurse
Vital signs CRF/clinical record Study nurse
Concurrent medications/OME Clinical record Study nurse
Study trial data – questionnaires – ASSIST, SLUMS, EORTC QLQ-C15-PAL CRF Patient, study nurse, medical officer `
Study trial data – ESAS, AKPS, RUG-ADL, PGIC, CGI-S/I, DASS – 21 CRF Patient, study nurse, medical officer `
Side effects – safety CRF, clinical record Study nurse, medical officer

All data collected will be kept in a patient file (identified by ID number only). All data will be stored in a locked filing cabinet. At completion of the study, all CRFs will be collated and archived. Electronic files will be password protected and held within a locked office. All patient files will be reconciled and stored along with all study materials, both hard copy and electronic, consistent with the regulations of the hospital regarding the retention and disposal of patient records.

The trial will be conducted with permission and in accordance with Queensland Health regulations on the use of medical cannabis and subject to approval and monitoring by each clinical site’s HREC [4, 22]. An independent DSMB to include a statistician, clinical pharmacologist, palliative care specialist and consumers, will be formed and will meet regularly, with primary responsibility for monitoring adverse and serious adverse events. All AE’s and SAE’s will be reviewed at a minimum of 6 monthly intervals, or more frequently if needed.

Discussion

The use of cannabis for symptom control continues to be a topical issue within medicine, and this study is the first placebo controlled, randomised trial to assess the efficacy of cannabinoids in advanced cancer patients. A major strength of this study is that it will target symptom burden as a whole, rather than individual symptoms, in an attempt to capture the improvement in general wellbeing reported anecdotally by many who have used cannabis [23, 24]. Randomisation with placebo is essential because of the well-documented over reporting of benefit in uncontrolled trials and high placebo response rates in cancer pain trials [25, 26]. The trial design is pragmatic, intended to allow as wide a range of participants as possible, to enable the results to be as real-world as possible. This study also allows for some data on dosing and formulation of CBD specifically.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Abbreviations

Australia-modified Karnofsky Scale

Alcohol, Smoking and Substance Involvement Screening Test

Clinical Global Impressions scale

Chemotherapy induced nausea and vomiting

Note for Guidance on Good Clinical Practice

Case Report Form

The Depression, Anxiety, Stress Scale

Data Safety Monitoring Board

European Organisation for Research and Treatment of Cancer

Edmonton Symptom Assessment Scale

Gold Coast Cancer Services

Green Dispensary Pty Ltd. (GD Pharma)

Good Manufacturing Practice

Human Research Ethics Committee

Mater Misericordiae Limited

Medical Research Future Fund

National Health and Medical Research Council

Oral Morphine Equivalent

Quality of Life

Queensland Palliative Care Research Group

Resource Utilisation Groups – Activities of Daily Living Scale

Serious Adverse Events

St Louis University Mental Status exam

Three times a day

Therapeutic Goods Administration

Total Symptom Distress Score

References

Singer AE, Meeker D, Teno JM, Lynn J, Lunney JR, Lorenz KA. Symptom trends in the last year of life from 1998 to 2010: a cohort study. Ann Intern Med. 2015;162(3):175–83.

Yates P. Symptom management and palliative Care for Patients with Cancer. Nurs Clin North Am. 2017;52(1):179–91.

Whiting PF, Wolff RF, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456–73.Qld Government. Public Health (Medicinal Cannabis) Act 2016;accessed 27/09/17 Available from: https://www.legislation.qld.gov.au/view/htmL/asmade/act-2016-053.

Qld Government. Public Health (Medicinal Cannabis) Act 2016;accessed 27/09/17 Available from: https://www.legislation.qld.gov.au/view/htmL/asmade/act-2016-053.

Elsohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 2005;78(5):539–48.

Health Canada. Cannabis (marihuana, marijuana) and the cannabinoids 2013. Available from: http://www.hc-sc.gc.ca/dhp-mps/marihuana/med/infoprof-eng.php.

Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr. 2008;30(3):271–80.

Zhornitsky S, Potvin S. Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals (Basel). 2012;5(5):529–52.

Niesink RJ, van Laar MW. Does Cannabidiol protect against adverse psychological effects of THC? Front Psychiatry. 2013;4:130.

National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. 2017.

Howard P, Twycross R, Shuster J, Mihalyo M, Wilcock A. Cannabinoids. J Pain Symptom Manag. 2013;46(1):142–9.

National Consensus Project for Quality Palliative Care. Clinical Practice Guidelines for Quality Palliative Care. 3rd ed: National Consensus Project for Quality Palliative Care; 2013. 70 p.

Hui D, Shamieh O, Paiva CE, Khamash O, Perez-Cruz PE, Kwon JH, et al. Minimal clinically important difference in the physical, emotional, and Total symptom distress scores of the Edmonton symptom assessment system. J Pain Symptom Manag. 2016;51(2):262–9.

Abernethy, A.P., Shelby-James, T.M., Fazekas, B.s, Woods, D., Currow, D.C. The Australian-modified Karnofsky Performance Status (AKPS) scale: a revised scale for contemporary palliative care clinical practice. BMC Pall Care. 2005, 4, 7.

Humeniuk R, Ali R, Babor TF, Farrell M, Formigoni ML, Jittiwutikarn J, De Lacerda RB, Ling W, Marsden J, Monteiro M, Nhiwatiwa S, Pal H, Poznyak V, Simon S. Validation of the alcohol, smoking and substance involvement screening test (ASSIST). Addiction. 2008;103:1039–47.

Tariq SH, N Tumosa, JT Chibnall, HM Perry III, and JE Morley. The Saint Louis University Mental Status (SLUMS) Examination for detecting mild cognitive impairment and dementia is more sensitive than the Mini-Mental Status Examination (MMSE) – A pilot study. 2006 Am J Geriatr Psych 14:900–10.

Williams BC, Fries BE, Foley WJ, Schneider D, Gavazzi M. Activities of daily living and costs in nursing homes. Health Care Financ Rev. 1994;15(4):117–35.

The Clinical Global Impressions Scale Applying a Research Tool in Clinical Practice. Joan Busner, PhD and Steven D. Targum, MD Psychiatry (Edgmont). 2007 Jul; 4(7): 28–37. Published online 2007 Jul.

Johnson CE, Bennett KS, Newton J, McTigue J, Taylor S, Musiello T, Lau PKH. A pilot study to assess the validity of the DASS-21 subscales in an outpatient oncology population. Psycho-Oncology. 2018;27:695–9.

Aaronson NK, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.

US Department of Health Human Services. Common terminology criteria for adverse events (CTCAE) version 4.0. National Cancer Institute. 2009(09–5410).

Qld Health. Clinical guidance: for the use of medicinal cannabis products in Queensland 2016. Available from: https://www.health.qld.gov.au/__data/assets/pdf_file/0023/634163/med-cannabis-clinical-guide.pdf

Luckett T, Phillips J, Lintzeris N, Allsop D, Lee J, Solowij N, et al. Clinical trials of medicinal cannabis for appetite-related symptoms from advanced cancer: a survey of preferences, attitudes and beliefs among patients willing to consider participation. Intern Med J. 2016;46(11):1269–75.

Swift W, Gates P, Dillon P. Survey of Australians using cannabis for medical purposes. Harm Reduction Journal. 2005;2:18.

Kunz R, Oxman AD. The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials. BMJ. 1998;317(7167):1185–90.

Hardy J, Quinn S, Fazekas B, Plummer J, Eckermann S, Agar M, et al. Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol. 2012;30(29):3611–7.

First hand account of medical cannabis stage 4 small cell lung cancer.

Medical disclaimer: This page is for informational purposes only and may not be construed as medical advice. The information is not intended to replace medical advice offered by physicians.

I wanted to share some information on our experience we had recently with my 84 year old Dad who was diagnosed with stage 4 small cell lung cancer in April 2019. This is by no means me stating any of what we did to be a cure but more just wanting to share what we have experienced so far and how my Dad is going.

In short Dad was diagnosed with stage 4 small cell lung cancer in April last year. In May while I was away working at the Finders Keepers Market in Sydney I got the phone call from my sister who was distraught and giving me the news that our beautiful Dad has been given only 3 months to live. I know 83 is a good innings but I guess we just weren’t ready for him to go let alone suffer a terrible death. Apparently small cell lung cancer (usually caused from smoking of which Dad was a very heavy one) is extremely aggressive and not treatable with chemo or radiation. Dad’s oncologist initially said because of Dad’s age that he was not eligible for those treatments anyway. Dad was always adamant that if he had cancer he wouldn’t do chemo, he has always said it is just left over mustard gas from the war. Fast forward one week the oncologist called him in again and said that because Dad is a very active 80 something year old that he could probably handle the chemo. Dad really wasn’t feeling like he was ready to die just yet and wanted longer to live. The oncologist said the only thing they could do was 6 rounds of chemo which MIGHT get him through to Christmas and that it would NOT cure his cancer it may just slow it down. If he did this he would be lucky to get to Christmas. Even though it went against everything he believed in Dad went along with it as they ushered him off to the oncology ward to start his first round of Chemo. Poor Dad, he did one round of chemo and came home. He started to lose his hair ( he proudly had a full head of gorgeous thick grey locks), he was nauseas, vomiting and eventually rushed to hospital in an ambulance when he collapsed and was taken to ICU and on the brink. His body was not dealing with the chemo. A few days later he told his doctor what he could do with this chemo therapy and decided he wanted to try some alternatives and was not going to continue with Chemotherapy.

Ash and I had been researching and found a lot of literature on medical marijuana and how CBD destabilises the cancer cells and THC can cause apoptosis (basically the cancer cell kills itself).

We watched youtube clips, read blogs, watched docos, anything we could do to educate ourselves. We found where we could source some oils locally where they were supplying cannabis oil to assist in not only cancer but also epilepsy, anxiety, nausea, chronic pain and all sorts of ailments. So we went out there and spoke with the most amazing and inspiring lady. She gave us all the info we needed and the oils (around $1500 worth) and off we went. (feel free to email me for more info on where we sourced them)

My Dad has never smoked a joint in his life. He is old school and always thought marijuana was the root of all evil. But we showed him some of the videos and he agreed to give it a try.

We bought him straight CBD paste and oil and then some very high THC which he needed to take 20 drops of. We thought we should give it to Ash first to try and holy crap.. it was so strong!! Ash basically ended up tripping all night and didn’t sleep and was a mess the next day. I was so worried. How was Dad going be able to take such high amounts of THC and deal with the extreme high it produced? We did more research and found that if it is taken anally or through the rear end that it by-passes the liver and and has no psychoactive effects. (you may need to ask a doctor about the specifics of that) so we tried that the next day with Ash the guinea pig, we mixed the oil down in some coconut MCT oil and put it in a syringe and he took it via the back door…. Voila.. he felt nice and relaxed but wasn’t stoned or tripping out. Great, Dad will be ok with this.

We also started researching all sorts of other treatments while Mum and Dad hitched up their caravan and made the trip from Eildon in Victoria and headed to our place in Northern NSW to start a full regime of cannabis oil, diet and anything else we could get our hands on to help him. This was big and so brave of them both, this was his life and we had it in our hands. Some of my family were not stoked , they were worried that Dad wouldn’t be back and they wouldn’t see him again or maybe that we were being reckless with his life but it was Dad’s choice and the chemo just wasn’t for him so we felt we had no choice and we knew that Mum and Dad needed our support to take on all of these different therapies. I am so proud of Dad for taking that risk and also being so open to fully immerse himself in this journey.

We also had to look in to how we would get his body back and were prepared for him to pass up here in our house if it came to that. Either way I was ok with it. I just wanted to pour all my love and everything I had into making Dad as comfortable and as healthy as possible.

So here is what we did.

CBD and THC

We have also spoken to a lot of people who had tried the oils and had no success with them but after talking with them realising perhaps they hadn’t had enough. You need A LOT of THC. As I said before Dad was to have 20 drops of very very high THC (2 drops would get me feeling pretty stoned). This is too hard for some people but again we found the suppository method was the best way around this. It’s not glamorous but there are worse ways to treat cancer. So THC at night as much as you can handle just before sleep is best for most people.. Straight CBD when you wake up can also dust off the the “mull over” and fogginess the next day. . We also made our own paste with our good friends from Mullumbimby using the Rick Simpson (RSO) method. To make your own you need at least one big plant and that should get you around 90 days worth of RSO oil. If you can’t make your own I suggest getting in contact with the Nimbin Hemp Embassy via Facebook and chatting with them. I could go on and on but in a nutshell our bodies have what is called an endocannabinoid system. The endocannabinoid system is a molecular system responsible for regulating and balancing many processes in the body, including immune response, communication between cells, appetite and metabolism, memory. Because CBD stimulates the endocannabinoid system, it helps to promote homeostasis in the body, reducing the sensation of pain and inhibiting inflammation. Research into the possible uses of CBD and other cannabis compounds is a growing area of study, meaning the list of potential benefits is likely to grow. But studies have found that it has a massive impact on cancer, Chrone’s disease, MS, fibromyalgia and all sorts of ailments. This is still illegal however some doctors are now prescribing CBD but only if you have exhausted all other legal avenues of treatment first. So in Dad’s case to be illegible for CBD and THC from the doctor he would have had to have had the 6 rounds of chemo and radiation before he would be considered. There is a tonne of info on the internet about CBD and THC so get googling.. Some good sources of info are

Youtube – Run From The Cure the sotry of Rick Simpson (the guy who pretty much found that cannabis could cure all sorts of things including cancer) https://www.youtube.com/watch?v=TIzP5pV8ZIY

Also there is a great doco on Netflix called Weed The People.

DIET

Firstly, from our research we found that cancer LOVES and feeds off sugar so that had to go. We cut all sugar from Dads diet, that included, grains (apart from buckwheat and quinoa), all fruit with the exception of berries and cantaloupe which he could have BEFORE a meal. We cut out dairy, meat, coffee and anything else that was acidic. We also found a lot of literature stating that cancer can not live in an alkaline environment so anything that was acidic was to go and we also gave him a drink of bi-carb soda in lemon water twice a day which is said to alkalise the body.

We did do some juicing if he was feeling up to it which would have a small green apple and lots of greens but some days he just wasn’t up to it.

Here is some more info

BREATHING

We had so much support from beautiful friends offering their support which we took them up on. Our gorgeous friend Lissie Turner from The Yoga Shack in ocean shores offered up her services and she came over and started Dad on some deep breathing exercises. We would breath and chant with him around the kitchen table each day which was so beautiful. The extra oxygen and the chanting which seems to regulate his exhale was really beneficial. After each session we would see the colour come back to his face. He laughed a lot too as we would chant “MAAAAAAAAAAA” on our exhale, we must have sounded like some strange cult. We had also read that oxygen can also kick cancers butt so we fully immersed in that as a daily ritual. We looked in to hyperbaric oxygen chambers as well but unfortunately Dad was too sick at that stage to travel that far (90 mins away) and it was also really expensive.

GRATTITUDE

We bought Dad a paper journal for him to start writing down what he was grateful for. Just 5 things a day. This also became a ritual for all of us. We would sit as a family before dinner and share what we were grateful for in that day or life in general. What a beautiful thing to do. To listen to our 83 almost 84 year old Dad telling us how grateful he was for life, his family, his breath and even his cancer which was clearly becoming a source of an outpouring of love and giving us all a thirst and gratitude for life.

ACCUPUNCTURE

We were also lucky enough to have another gorgeous friend Danni Sartori who is an incredible acupuncturist and neurolink specialist come in and give Dad some treatments. This was also completely foreign to him but he took it on and really enjoyed it.

Vitamin C IV Drips.

We also consulted with our local GP here in Ocean Shores, and are lucky enough to have the most incredible GP Dr Marcus Hewitson at Ocean Shores Nutritional & Environmental Medicine who saw Dad and supported us in our alternative therapies and also got Dad on some Vitamin C and Vitamin B IV drips. These were expensive but you could really see his energy increase after each one.

This process was over about 8 weeks and was pretty scary at times. I don’t know if it was his body detoxing, the cancer spreading or even retreating but some days Dad couldn’t get off the couch. He would have nights of vomiting, diarrhoea, nausea, headaches, body aches, night sweats and then some days he was great. By the 8 week mark we were rejoicing the fact he was still with us and seemed to be getting a lot stronger. By this stage he was readying to go home and we were still a little worried about him driving home. Just before they left my Uncle called me and told me about a man name Joe Tippens who had the same cancer as Dad and was riddled it it. He had treated and cured his cancer using dog worming tablets!! Yes that’s right, dog worming tablets as well as turmeric, vitamin E and CBD Oil. So we looked in to that and thought what the hell let’s do that too. Dad was up for anything so we ordered some on the internet and started that protocol as well. The active ingredient had been found to kill cancer cells in mice. The actual ingredient is called Fenbendazole. Dad would take the tablet for 3 days then have 5 days off and did that for 8 weeks. Along with the turmeric tablets and vitamin E and the cannabis oil he was already taking. As you can tell we were pretty much ready to try anything.

Mum and Dad left our place at the start of August and I was still feeling a little apprehensive but he wasn’t getting any worse and from what I can tell he seemed to be getting a little better. Our hope was that he would make it to Christmas but the rest of the family decided to have an early Christmas in August which also celebrated his 84 th birthday and just in case he didn’t get to December. By this stage his hair had started to grow back and he was slowly getting better and better each day.

We are now in February 2020 and I just got back from Mum and Dad’s place. Since Christmas he has gotten stronger and stronger. His hair has completely grown back.. in fact he has had three haircuts since then. He is back playing golf most days, fishing and getting out into the garden. He and Mum are even planning a trip to NZ together. I can’t describe how much better he looks. To look at him you couldn’t even tell he had cancer. Dad was contacted by his oncologist who just wanted to touch base and was frankly shocked that he was still alive and looking so good. Dad has put on all 6 kilos he lost when he was sick and has vitality and feels amazing within himself. At this stage he doesn’t want to do any tests to see where the cancer is at as he if worried that if it has spread that it will set him back. He said he feels amazing and that is all he needs to know. I am inclined to agree although part of me would love to know if the cancer has gone or halted. The main thing is he got WAY past the initial prognosis of 3 months, he got to Christmas with flying colours and we are now 11 months past his initial diagnosis and he looks healthier than he has in years. A lady from their home town stopped me recently and said “When your Dad left to go your place in June none of us thought we would see him again.. we still can’t believe it and he looks 20 years younger!” .

So all I can say is we don’t know where his cancer is at, but he went from being at deaths door to an extremely healthy almost 85 year old man who is back to doing all the things he loves with an amazing quality of life. We are so grateful to everyone who has helped and supported us on this journey. It is one that I feel privileged to be a part of.

I am so sad to share that my Dad passed away 7 weeks ago (24/08/2021) after a 2 and a half year “prolonged remission”. His cancer came back and spread to his brain and liver. Dad had stopped the diet and everything except for the Canabis Oil. I wonder if he had kept going with it all if he would kept the cancer at bay? He did have an amazing 2 years, pain free, fishing and golfing right up until his last couple of months. His quality of life was just amazing and he used his extra time to enjoy his time with his family and friends. From an initial prognosis of 3 months to live (possibly 6 months if he had 6 rounds of chemo) to 2 and a half healthy years, I think he did exceptionally well. I have grappled with taking down this blog as I thought his ending might cause others to give up hope, but I do think we had a wonderful outcome. Dad wanted to live for one more year and he got two awesome years. He passed at home with his family around him. He never once complained of any pain in fact he insisted he had none. He just faded a little more each day. It was very peaceful.
It was a beautiful ending, a lot of singing, celebrating, tears and laughter and lots of foot rubs for Dad.
Whether you or your loved one is fighting cancer, don’t give up hope. Every day is a precious gift cherish them all.

I’m sorry I forgot to mention that my age is 32yrs old, smoker. 1-2 cigs a day soon to be zero from a pack a day to almost 2 pack a day. My dad skied not have cancer and is almost 60 , he has had a triple bypass surgery and still smokes a lot but he is happy, does not have a deadly cough or anything. It’s crazy how the body works.. never smoked not even close to the amount that he dad and I have stage 3 lung cancer.. wow. Anyway..

Never take this post down. Ppl need to see it. I was recently diagnosed with small cell carcinoma, it traveled to my brain of course , it’s been maybe 7 months since diagnosed. Currently taking radiation and immunotherapy and just daily supplements and diet. I believe I am going today to but everything needed for the tippens protocol. Wish me luck people. Any advice? Email me at [email protected] or text me at (334) 425-5025

Hi Dani,
Please don’t take down your post. It’s a beautiful story of love and living with cancer.
I am a strong believer in the cannabis oils for cancer treatment as well as the holistic approach with diet and lifestyle.
Your a wonderful daughter to have taken this journey with your beautiful Dad. I’m sure he was forever grateful and proud of your efforts.
Blessings to you and your family on your Dad’s passing..

Your story is inspirational. My Dad was given a similar diagnosis earlier this year. I’d love to email you re. suppliers ect.

In 2020 I was diagnosed with breast cancer. Normally, the way we treat cancer is with some combination of surgery, chemotherapy, and radiation therapy. In my case because of the metastasis it was also not the best option for me. The lump in my breast was too large for a lumpectomy and I opted not to have a mastectomy doctors told me to increase my vitamin D level because this helps cancer patients in a variety of ways. Initially I took vitamin D supplements, but trust me it was not getting any better so I came online to see if there was any possible way I could fight this disease . I saw a lot of testimonies of how Dr Ohikhobo cures Cancer and all kinds of diseases with natural herbs so I decided to give it a try. I contacted him to see if it was possible for him to help me get rid of this disease. I was amazed by the results. After taking his natural herbs for just 21 days I got cured completely and my life is back to normal again. I will forever be grateful to Dr Ohikhobo. Below is his Contact info for me. I believe there is no disease this man can’t cure.
Email: drohikhoboherbalcenter @ gmail .com
His WhatsApp +1-740-231-2427